Literature DB >> 18314592

Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression.

S Spaderna1, O Schmalhofer, F Hlubek, A Jung, T Kirchner, T Brabletz.   

Abstract

Invasion by colorectal carcinomas is characterized by an epithelial-mesenchymal transition (EMT)-like de-differentiation of the tumor cells. However a re-differentiation towards an epithelial phenotype, resembling a mesenchymal-epithelial transition (MET) is detectable in metastases. This indicates that malignant progression is based on dynamic processes, which can not be explained solely by irreversible genetic alterations, but must be additionally regulated by the tumor environment. The main oncoprotein in colorectal cancer is the Wnt-pathway effector beta-catenin, which is overexpressed due to mutations in the APC tumor suppressor in most cases. EMT of the tumor cells is associated with a nuclear accumulation of the transcriptional activator beta-catenin, which is reversed in metastases. Nuclear beta-catenin is involved in two fundamental processes in embryonic development: EMT and stem cell formation. Accumulating data demonstrate that aberrant nuclear expression of beta-catenin can confere these two abilites also to tumor cells. The unusual combination of EMT with stem cell competence might result in a migrating tumor stem cell, which drives tumor invasion and metastasis.

Entities:  

Mesh:

Year:  2007        PMID: 18314592

Source DB:  PubMed          Journal:  Verh Dtsch Ges Pathol        ISSN: 0070-4113


  22 in total

Review 1.  New promising drug targets in cancer- and metastasis-initiating cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2010-03-23       Impact factor: 7.851

Review 2.  Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

Review 3.  New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence.

Authors:  M Mimeault; S K Batra
Journal:  Histol Histopathol       Date:  2010-08       Impact factor: 2.303

Review 4.  Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.

Authors:  Anoop K Yadav; Neetin S Desai
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

5.  GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition.

Authors:  Zhou Yang; Dejun Wu; Yusheng Chen; Zhijun Min; Yingjun Quan
Journal:  Cancer Biol Ther       Date:  2019-05-07       Impact factor: 4.742

6.  CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.

Authors:  A Lugli; E Karamitopoulou; I Panayiotides; P Karakitsos; G Rallis; G Peros; G Iezzi; G Spagnoli; M Bihl; L Terracciano; I Zlobec
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

7.  E-Cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth.

Authors:  M Farmakovskaya; N Khromova; V Rybko; V Dugina; B Kopnin; P Kopnin
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 8.  Surfing the big WAVE: Insights into the role of WAVE3 as a driving force in cancer progression and metastasis.

Authors:  Khalid Sossey-Alaoui
Journal:  Semin Cell Dev Biol       Date:  2012-10-29       Impact factor: 7.727

9.  The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion.

Authors:  Khalid Sossey-Alaoui; Katarzyna Bialkowska; Edward F Plow
Journal:  J Biol Chem       Date:  2009-10-01       Impact factor: 5.157

Review 10.  Diverse roles of miR-335 in development and progression of cancers.

Authors:  Long-Ji Luo; Dan-Dan Wang; Jing Wang; Fan Yang; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2016-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.